House
GuidelinesCalculatorsPricingBlog
Ask House ↗
Guidelines↗Calculators↗Pricing↗Blog↗
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
Back to guidelines
Oncology

Colorectal cancer

NICE · 2021 edition / updateSource checked 29 October 2026
Read the source publication
House clinical summary

Scope

NICE NG151 covers colorectal-cancer treatment decisions, selected molecularly directed therapies and follow-up. Rectal and colon pathways differ, and stage, resectability, biomarkers, prior treatment and patient preferences determine which options apply. The live recommendations also link to newer technology appraisals; their eligibility and prescribing detail remains necessary when selecting systemic treatment.

Written by House with AI assistance · AI-assisted source check 29 October 2026.

This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.

Discuss goals, functional effects and urgent obstruction

  • Explain the available surgical, radiotherapy, systemic-treatment and palliative options, including bowel and sexual function, quality-of-life and independence effects. Discuss why plans may change and the possibility, purpose and likely duration of a stoma. [1]
  • For acute left-sided large-bowel obstruction, consider a stent when treatment intent is palliative. When potentially curative treatment is suitable, offer either stenting or emergency surgery. [1]
  • For people with Lynch syndrome, consider daily aspirin for more than 2 years to reduce colorectal-cancer risk. The recommendation does not specify an aspirin dose in this section, and the preventive decision requires discussion with the patient. [1]

Match rectal treatment to stage and surgical circumstances

  • For early rectal cancer, cT1–T2, cN0, M0, discuss transanal excision, endoscopic submucosal dissection and total mesorectal excision to reach a shared decision. Do not offer preoperative radiotherapy for this group except in a clinical trial. [1]
  • Offer preoperative radiotherapy or chemoradiotherapy for cT1–T2, cN1–N2, M0 rectal cancer, or cT3–T4, any cN, M0 disease. Offer surgery for these stages when the tumour is resectable. [1]
  • If someone with a complete clinical and radiological response to neoadjuvant treatment wishes to defer surgery, explain recurrence risk and the guideline’s uncertainty about selecting patients for deferral. Encourage trial participation and collect registry data when deferral is chosen. [1]
  • Offer laparoscopic rectal surgery; consider open surgery where clinically indicated. Robotic surgery should be considered only within established programmes with audited outcomes, and transanal total mesorectal excision only in research. [1]
  • Consider specialist-centre referral for locally advanced primary or recurrent rectal cancer that may require multivisceral or beyond-total-mesorectal-excision surgery. [1]

Retain the population and duration of chemotherapy recommendations

  • For stage 3 rectal cancer, pT1–4, pN1–2, M0, treated with short-course radiotherapy or no preoperative treatment, offer CAPOX for 3 months; if unsuitable, offer FOLFOX for 3 to 6 months or a single fluoropyrimidine for 6 months. Base choice on histopathology, fitness, preferences, comorbidities and age. [1]
  • For stage 3 colon cancer, pT1–4, pN1–2, M0, offer CAPOX for 3 months, or if unsuitable FOLFOX for 3 to 6 months or single-agent fluoropyrimidine for 6 months. Consider preoperative systemic treatment for cT4 colon cancer. [1]

Use biomarkers and prior therapy to identify systemic options

  • Test RAS and BRAF V600E in every patient with metastatic colorectal cancer who is suitable for systemic anticancer treatment. Treatment branches also distinguish high microsatellite instability or mismatch-repair deficiency. [1]
  • For untreated unresectable or metastatic MSI-high or mismatch-repair-deficient disease, nivolumab plus ipilimumab is an option. Pembrolizumab is an option for untreated metastatic disease in this biomarker group and should stop after 2 years or earlier progression. Consult the linked appraisals for full eligibility. [1]
  • For untreated metastatic RAS-wild-type disease, panitumumab with FOLFOX or FOLFIRI is an option. Cetuximab with either chemotherapy combination is an option when disease is also EGFR-expressing. [1]
  • Bevacizumab with fluoropyrimidine-based chemotherapy is an option for untreated or second-line metastatic disease when targeted treatments or immunotherapy are unsuitable and chemotherapy would otherwise be offered. [1]
  • After fluoropyrimidine-based combination chemotherapy, nivolumab plus ipilimumab is an option for metastatic MSI-high or mismatch-repair-deficient disease. Pembrolizumab is an option for unresectable or metastatic disease in this setting only when that combination cannot be used, stopping at 2 years of uninterrupted treatment or earlier progression. [1]
  • Encorafenib with cetuximab is an option after previous systemic treatment for BRAF V600E-mutated metastatic colorectal cancer. This is a biomarker- and treatment-history-specific recommendation. [1]

Discuss local treatment in a specialist multidisciplinary team

  • For colorectal liver metastases, consider resection after multidisciplinary discussion and consider perioperative systemic treatment if resection is suitable. If resection is unsuitable, consider chemotherapy with local ablation through a specialist team. [1]
  • For lung metastases suitable for local therapy, consider metastasectomy, ablation or stereotactic radiotherapy through a team including thoracic surgical and nonsurgical-ablation expertise. Consider biopsy of a solitary lung lesion to exclude a primary lung cancer. [1]
  • For metastases confined to the peritoneum, offer systemic anticancer therapy and discuss specialist-centre referral within the multidisciplinary team to consider cytoreductive surgery and HIPEC. This is a referral consideration, not automatic eligibility for the procedure. [1]

Monitor recurrence and help with bowel dysfunction

  • After potentially curative surgery for nonmetastatic colorectal cancer, offer recurrence and metastasis surveillance for the first 3 years, including serum CEA and CT of the chest, abdomen and pelvis. [1]
  • Explain low anterior resection syndrome before potentially sphincter-preserving surgery. Assess symptoms with a validated patient questionnaire; offer appropriate dietary or medication treatment for bowel dysfunction and seek secondary-care advice if unsuccessful. [1]

Limitations and use

  • This is a selected treatment summary, not a complete staging, drug-prescribing or biomarker-testing protocol. It does not reproduce every later-line therapy, primary-tumour surgery decision or local-radiotherapy restriction.
  • Use the linked technology appraisals for full indication criteria, treatment duration and prescribing details. Drug availability, funding and off-label status may differ in India.
  • The rectal-cancer surgery-deferral statement reflects this guideline’s wording; it is not a complete contemporary organ-preservation surveillance protocol.
  • Follow-up test frequency, colonoscopic surveillance and management of hereditary syndromes require the relevant detailed pathways.

This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.

Summary sources

  1. 1
    Colorectal cancer

    Selected recommendation material consulted

Clinical guideline

Publication details

Issuing organisation
NICE
First published
29 January 2020
Publisher’s latest update
15 December 2021
Resource type
Clinical guideline · House clinical summary
Source setting
United Kingdom

The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.

On this page

  • Scope
  • Discuss goals, functional effects and urgent obstruction
  • Match rectal treatment to stage and surgical circumstances
  • Retain the population and duration of chemotherapy recommendations
  • Use biomarkers and prior therapy to identify systemic options
  • Discuss local treatment in a specialist multidisciplinary team
  • Monitor recurrence and help with bowel dysfunction
  • Limitations and use
  • Summary sources
  • Publication details
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House